DDInter997 DDInter1676
Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and also administered in combination with other drugs for the management of CF.[L6814,L6979,L6847] Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion channel involved in the transport of chloride and sodium ions across cell membranes. CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract. Alterations in the CFTR gene result
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Ivacaftor {u} (Compound) binds {v} (Gene) CYP3A4
Ivacaftor {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A Inhibitors
Ivacaftor {u} (Compound) causes {v} (Side Effect) Pleuritic pain
Ivacaftor {u} may cause a minor interaction that can limit clinical effects when taken with {v} Doravirine
Ivacaftor {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Ivacaftor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etonogestrel
Ivacaftor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Avapritinib
Ivacaftor {u} may lead to a major life threatening interaction when taken with {v} Fluconazole
Ivacaftor {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Ivacaftor (Compound) binds CYP3A4 (Gene)
Ivacaftor (Compound) is included by Cytochrome P450 3A Inhibitors (Pharmacologic Class)
Ivacaftor (Compound) causes Pleuritic pain (Side Effect)
Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Doravirine
Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Modafinil
Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Etonogestrel
Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Avapritinib
Ivacaftor may lead to a major life threatening interaction when taken with Fluconazole
Ivacaftor may lead to a major life threatening interaction when taken with Crizotinib